Alimu Dayimu

9PUBLICATIONS
59CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCardiology (incl. cardiovascular diseases)Stochastic analysis and modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Mar 19, 2026
Reply to: Interpreting Circulating Tumor DNA-Guided Risk Stratification After First-Line Therapy.

Joanna A Krupka, Alimu Dayimu, Daniel J Hodson

|Jan 06, 2026
Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial.

Rebecca A Burrell, Sanjeev Kumar, Elena Provenzano

|Dec 22, 2025
Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.

Joanna A Krupka, Ilias Moutsopoulos, Natasha H Cutmore

|Jul 12, 2025
Seamless monotherapy-combination phase I dose-escalation model-based design.

Libby Daniells, Thomas Jaki, Alimu Dayimu

|May 13, 2025
Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer.

Harveer Dev, Mark Linch, Krishna Narahari

|Aug 22, 2024
Trial to assess the tolerability of using felodipine to upregulate autophagy as a treatment of Huntington's disease (FELL-HD): a phase II, single-centre, open-label, dose-finding trial protocol.

Katie Andresen, Emma Cutting, Dimitrios Apostolopoulos

Pageof 2

Frequent Collaborators

2 joint publications

Daniel J Hodson

2 joint publications

Joanna A Krupka

1 joint publications

Juan W Valle

1 joint publications

Duncan Jodrell